13 April 2015Americas

Hedge fund manager defends IPR petitions

Dallas-based hedge fund Hayman Capital Management has defended its owner’s decision to challenge a clutch of patents using the inter partes review (IPR) procedure.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Hedge fund manager targets Jazz in another IPR patent challenge

9 April 2015 A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Hedge fund manager targets Jazz in another IPR patent challenge

9 April 2015 A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.

More on this story

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

Hedge fund manager targets Jazz in another IPR patent challenge

9 April 2015 A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims